NovaDel pilot PK study compares oral spray to Viagra

By Nick Taylor

- Last updated on GMT

Related tags: Pharmacology, Viagra

Data from a study comparing an oral spray formulation of sildenafil citrate to Viagra has been presented by NovaDel Pharma.

NovaDel develops formulations using its proprietary system, NovaMist, to realise the benefits of delivery via an oral spray. NovaMist formulations of treatments for insomnia and angina have been approved and NovaDel is now looking to move into the erectile dysfunction market.

An oral spray formulation of sildenafil citrate could have a faster onset of action, lower dose requirements and improve patient compliance and convenience compared to other dosage forms.

Potential benefits of administration via an oral spray are realised because the treatment enters the bloodstream through sites in the oral mucosal cavity. This area has a high concentration of blood vessels and a relatively permeable membrane, resulting in fast absorption.

To further development NovaDel performed a pilot pharmacokinetic (PK) study comparing its product, Duromist, to the tablet formulation of sildenafil citrate, marketed by Pfizer as Viagra.

Results from the 24-person study show 20mg, or two sprays, of Duromist is equivalent, in terms of systemic exposure (AUC0-inf), to a 25mg Viagra tablet. Mean AUC0-inf for 30mg of Duromist was 40 per cent higher than for 25mg of Viagra.

No adverse events were reported and there was no evidence of oral irritation after administration of up to three doses of Duromist. Furthermore, vital signs were within normal range and no changes in electrocardiograms were observed.

Next step

NovaDel and the US Food and Drug Administration (FDA) are now reviewing the results of the study. This will help define clinical trial requirements as a pathway to new drug application (NDA) approval.

This initial clinical study provides NovaDel with a solid foundation for our future clinical development efforts​”, said Steven Ratoff, chairman of the board, president and CEO at NovaDel.

Related topics: Delivery technologies, Ingredients

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us

Products

View more

Webinars